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Background: Continuous positive airway pressure (CPAP) treatment improves the risk of cardiovascular events in
patients suffering from severe sleep apnea-hypopnea syndrome (SAHS) but its effect on the link between delta
power band that is related to deep sleep and the relative cardiac vagal component of heart rate variability, HFnu of
HRV, is unknown. Therefore, we tested the hypothesis that CPAP restores the link between cardiac autonomic
activity and delta sleep across the night.
Methods: Eight patients suffering from severe SAHS before and after 4 ± 3 years of nasal CPAP treatment were
matched with fourteen healthy controls. Sleep EEG and ECG were analysed to obtain spectral sleep and HRV
components. Coherence analysis was applied between HFnu and delta power bands across the first three sleep
cycles.
Results: Sleep characteristics and spectral HRV components were similar between untreated patients, treated
patients and controls, with the exception of decreased Rapid Eye Movement duration in untreated patients.
Coherence and gain values between HFnu and delta EEG variability were decreased in untreated patients while gain
values normalized in treated patients. In patients before and during long-term CPAP treatment, phase shift and
delay between modifications in HFnu and delta EEG variability did not differ from controls but were not different
from zero. In healthy men, changes in cardiac vagal activity appeared 9 ± 7 minutes before modifications in delta
sleep.
Conclusions: Long-term nasal CPAP restored, in severe SAHS, the information between cardiovascular and sleep
brainstem structures by increasing gain, but did not improve its tightness or time shift.Background
Increased cardiovascular events reportedly occur in the
early morning hours [1,2]. Interaction between cardiac
autonomic activity and sleep was studied to explain this
increased incidence [3-5].
The causal link between sleep apnea-hypopnea syn-
drome (SAHS) and cardiovascular morbidity has remained
controversial for many years [6,7] but there is now strong
evidence that sleep apnea is an independent risk factor for
cardiovascular disease [8]. Imbalance of cardiac sympatho-
vagal activity was found in SAHS but exact physiological* Correspondence: fabrice.jurysta@erasme.ulb.ac.be
1Sleep Laboratory and Laboratory of Psychiatric Research, Department of
Psychiatry, Erasme Academic Hospital - ULB, Brussels, Belgium
Full list of author information is available at the end of the article
© 2013 Jurysta et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orprocess involved in cardiac dysregulation remained un-
clear. Apnea induces bursts in peripheral sympathetic ac-
tivity [9] and raises vagal activity [10]. Patients suffering
from SAHS showed decreased relative cardiac vagal influ-
ence [11-13] and had inadequate sympatho-vagal responses
to the environment [14] or to sleep stage changes [15,16].
In patients suffering from SAHS, continuous positive
airway pressure (CPAP) treatment improved sleep archi-
tecture [17,18], cardiovascular indices [19,20] and other
comorbidities such as metabolic syndrome, cardiovascular
diseases or asthma [21-24]. Only a few studies have evalu-
ated the impact of long–term CPAP treatment on the
cardiac sympatho-vagal balance. The majority showed an
increase in vagal predominance according to the spectral
components of heart rate variability (HRV) after CPAPLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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conflicting results [25,26]. Some authors also studied the
evolution of cardiac sympathetic and vagal HRV compo-
nents across sleep stages in severely apneic patients
treated by CPAP [27,28]. Results were limited to the first
night of treatment.
No studies have investigated the impact of long-term
CPAP treatment on spectral HRV components across
sleep stages, or the evolution of the link between HRV
and deep sleep across the night in severely apneic patients
treated by CPAP, in comparison to healthy controls.
HRV components have been studied across sleep stages
in healthy young and middle-aged men. All authors found
that heart rate decreased during non-Rapid Eye Move-
ment (NREM) sleep in comparison to Rapid Eye Move-
ment (REM) sleep or wakefulness [3,4,29]. Cardiac vagal
activity, which is related to the spectral component of
High Frequency (HF) of HRV and which oscillates at the
respiratory frequency, was found to increase during
NREM sleep, however it decreased during REM sleep and
wakefulness [5,30-32]. Low frequency power (LF) of HRV
is related to the sympathetic influence within the cardiac
sympatho-vagal balance [30] although some controversy
exists on this point [33,34]. These spectral HRV compo-
nents are expressed in absolute units (in millisecondes2)
but when expressed in normalized units (nu) they may
reflect more accurately the relative influence of one sys-
tem versus the other on HRV [34]. As HFnu is defined
as HF/(HF + LF), HFnu corresponds to 1-LFnu. An increase
in HFnu is proportionally associated to a decrease in LFnu
and conversely. HFnu is also considered as a better reflec-
tion of the relative cardiac vagal influence than absolute
HF power [30,34,35]. Moreover, LF/HF is also used to
measure the influence of sympathetic or vagal activity on
the cardiac sympatho-vagal balance [30,34,35].
Spectral analysis can be also applied to EEG signal to
define five specific frequency power bands that are delta,
theta, alpha, sigma and beta power bands. Each of them
has a specific cyclic alternating pattern throughout the
night and the maximum of each sleep EEG frequency
power band is specifically related to sleep stages [36-39].
Therefore, the relationship between cardiac vagal activ-
ity and sleep EEG power bands has been investigated
[40-43]. The link between normalized HF HRV and delta
power bands, of which the maximum was associated with
sleep stages 3 and 4 of NREM sleep [39], was considered a
stronger link compared to relationships between HFnu and
the different normalized sleep EEG power band [42].
Moreover, modifications in HFnu preceded modifications
in the normalized delta power band by 9 ± 7 to 12 ± 5 mi-
nutes in healthy middle-aged and young men, respectively
[42,43]. Severe SAHS particularly altered the link between
cardiac vagal influence, HFnu, and delta sleep EEG by de-
creasing coherence and gain values and by altering thephase shift or the delay between occurrence of modifica-
tions in both signals [16].
As CPAP treatment could improve the cardiac sym-
patho-vagal activity, as well as sleep architecture, in pa-
tients suffering from severe SAHS, we tested the
hypothesis that the altered link between the relative car-
diac vagal influence and delta sleep should be improved
by CPAP treatment in severely apneic patients.
We assessed the link between normalized HF HRV
and delta power bands throughout the night in severely
apneic patients before and after at least one year of
nasal CPAP (nCPAP) treatment compared with healthy
matched controls.Methods
Subjects
Patients suffering from severe SAHS and treated by nasal
CPAP during at least one year were selected retrospect-
ively, provided they did not develop any cardiovascular
disease or a mental or neurological disorder. They had
been admitted in the Sleep Laboratory for two consecutive
nights to diagnose SAHS, and to exclude other sleep
disorders, such as parasomnia. Subsequently, record-
ings were performed at least one year after all adjust-
ments of CPAP treatment were done. Adjustments
included a sleep apnea-hypopnea index (AHI) ≤ 10
events/hour and an absence of side effects reported by
patients as skin irritation, dry throat, cough. Patients
were recommended to maintain CPAP during a mini-
mum of 5 hours every night. Moreover, CPAP machine
documented the mean use duration.
Apnea was scored when complete breathing cessation
was longer than 10 seconds. Hypopnea was noted if venti-
lation was reduced to less than 50% of the pre-hypopnea
level and associated with a decrease in arterial O2 satur-
ation greater than 3% or with arousal. Apnea was defined
as obstructive, central or mixed and reported as the
apnea-hypopnea index (AHI) per hour based on the ratio
of apnea to total sleep time (TST). SAHS was considered
severe if the apnea-hypopnea index was greater than 30
events/hour [44].
During each hospitalization, sitting systolic and dia-
stolic blood pressures (SBP and DBP) were measured by
a mercury sphygmomanometer in standardized condi-
tions. Mean SBP and DBP were obtained for each pa-
tient. Physical examination as well as blood and urinary
analyses were performed to exclude somatic pathologies.
Patients were matched for age and gender with
healthy controls. Healthy men were recorded during
three successive nights. The first night was used to provide
accommodation to the study procedure and exclude sleep
pathologies. Psychiatric and somatic disorders were also
excluded. Mean SBP and DBP were calculated.
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medication or over-the-counter (OCT) substances. Caffeine
consumption was limited to 400 mg/day until 6 PM. Al-
cohol was tolerated for very small quantities until 6 PM.
Two apneic patients and one control regularly smoked
more than 20 cigarettes/day.
Participants and controls were told to go to sleep at
approximately 22:30 hours and woke spontaneously in
the morning. Sleeping during the day was not allowed.
Controls received a detailed description and demonstra-
tion of the procedure and signed an informed consent
form. The local ethics committee of the Erasme Academic
Hospital approved the study protocol.
Recordings
For untreated patients, sleep EEG and ECG of the second
night were used for analysis. For controls, recording the
second or the third night was used, choosing the recording
without artifacts. Artifacts were defined as electrical para-
sites on recordings, insertion of QRS complexes in EEG
signals or deviation of EEG signals from the baseline. If
neither the second nor the third night showed artifacts,
one of them was randomly selected for analyses. For CPAP
treated patients, the night of the second hospitalization to
check CPAP treatment was used for analysis. Therefore,
we analysed ECG and EEG recordings of the same patients
before and during nasal CPAP treatment.
Analyzed EEG and ECG signals were obtained from a
19-channel digital polygraph (Brainnet, Medatec, Brussels,
Belgium) where EEG electrodes were Cz-Ax (Ax is a mas-
toid reference) and ECG electrodes were positioned in the
fifth intercostal space and the mid-clavicular line (V4) or
horizontally even with V4 in the mid-axillary line (V6).
Polygraph was composed of three EEG (Fz-Ax, Cz-Ax,
Oz-Ax), two electrooculograms, one submental electro-
myogram, ECG with one derivation (V4 or V6), a pulse-
oximetry (Biox 3740, Ohmeda, Louisville, CO) to detect
oxyhemoglobin saturation, oro-nasal thermistors (Infinity,
Sleepmate Technologies, Midlothian, VA), thoracic and
abdominal piezo-electric sensor straps to detect respi-
ratory movements (Resp-EZ, Sleepmate Technologies,
Midlothian, VA), and ankle piezo-electric movements
strain gauges to detect periodic leg movements (Moving
images, Sleepmate Technologies, Midlothian, VA).
Signals were filtered and sampled at 200 Hz. Data were
digitized with a 12 bit analog-to-digital converter and
recorded in a digital format that we developed (Endymion,
1993–2012, Sleep laboratory, Erasme Academic Hospital –
ULB) to be read and stored in the EDF file format [45].
EEG and ECG were stored at 100 and 200 Hz, respectively.
ECG was upsampled at 400 Hz to obtain a maximum of
precision for RR-intervals (RRI) measurement. RRI is de-
fined as the duration of two successive R waves of the QRS
complex on sleep ECG.Data analysis
Using the Endymion software, each 20-second epoch of
the sleep EEG was visually scored in sleep stages (1 to 4,
REM and wakefulness) in accordance with Rechtschaffen
and Kales criteria [46]. Fast Fourier transform was ap-
plied to each five second window and results were then
averaged every 20 seconds to obtain one point of spec-
tral power every 20 seconds. The spectral power was
scaled so that the power of a 50 μV digitized sine wave
was 1250 (μV)2. The frequency limits of delta EEG
power band were 0,5 and 3,0 Hz included. Delta power
band was expressed in normalized units defined as the
ratio between the power value within the specific fre-
quency power band and the full night mean power value
of the delta power band [47,48].
QRS complexes were automatically detected and an al-
gorithm that we previously developed [42] computed
RRI time series. Premature ventricular contractions and
ectopic beats, as well as artifacts were removed and
linearly interpolated with surrounding values in regards
to the RRI time series if RRI < 350 msec or RRI > 1500
msec. RRI time series as well as all detected and interpo-
lated events were visually inspected and corrected if ne-
cessary. RRI time series were resampled at 8 Hz. In
accordance with the Task Force of the European Society
of Cardiology and the North American Society of Pacing
and Electrophysiology [33], we obtained cardiac spectral
components of heart rate variability (HRV) every 20 sec-
onds from a 120-seconds window that is shifted ahead
20 seconds by 20 seconds on the RRI time series [42].
We then obtained a power value for total frequency
(TF) [0,01-0,4 Hz], very low frequency (VLF) (<0,03 Hz),
low frequency (LF) [0,04-0,15 Hz] and high frequency
(HF) [0,15-0,40 Hz] of HRV every 20 seconds. Thus, we
reached synchronous power values every 20 seconds for
EEG and ECG spectral components. HF or LF HRV pow-
ers are expressed in absolute (ms2) or normalized units
(nu) that are the ratio between HF and the sum (HF + LF)
[30,49]. In this sense, LFnu = 1-HFnu. Values for LFnu are
not reported in the results. Cardiac sympatho-vagal
influence is also described by the LF/HF ratio [35,49].
Data analysis as fast Fourier transform or HRV compo-
nent calculations were computed with the software pack-
age Matlab and its signal processing toolbox (Matlab
R2007b with Signal processing Toolbox 6.8, The Math
Works Inc., USA).
A detailed description of recordings and data analysis
can be found in a previous publication [42].
Coherence analysis
The coherence analysis is a method that characterizes the
linear relationship between two signals in the frequency
domain [50]. In our study, we applied this method to
measure the link between HFnu, which represents the
Table 1 Demographic parameters
SAHS patients SAHS patients Healthy
controlsbefore CPAP with CPAP
N 8 8 14
Age (years) 45,6 ± 6,7 49,9 ± 7 44,0 ± 6,2
BMI (kg/m2) 30,45 ± 5,75* 31,87 ± 4,5* 24,13 ± 2,34
SBP (mmHg) 110,0 ± 22,7 120 ± 30,7 118,2 ± 11,7
DBP (mmHg) 90,0 ± 31,6 99,3 ± 24,9* 70,4 ± 8,9
Nicotine (cig/day) 8,13 ± 10,33 0,00 ± 0,00 2,64 ± 7,19
Alcohol (U/day) 0,75 ± 1,66 0,67 ± 1,16 0,36 ± 0,6
Caffeine (100 mg/day) 2,63 ± 2,05 3,00 ± 0,00 2,72 ± 2,05
AHI (evts—/h) 63,50 ± 22,89*** 5,50 ± 4,38 3,79 ± 3,17
OAI (evts—/h) 16,90 ± 12,38*** 1,37 ± 2,15 0,88 ± 1,10
CAI (evts—/h) 6,65 ± 5,71** 0,60 ± 1,45 0,72 ± 1,24
MAI (evts—/h) 22,21 ± 21,43*** 0,1 ± 0,28 0,02 ± 0,08
HypoI (evts—/h) 17,51 ± 9,22*** 3,48 ± 2,50 2,21 ± 1,63
Mean SaO2 (%) 87,88 ± 5,36* 92,50 ± 2,00 93,19 ± 1,47
Bilateral PLMI (evts—/h) 11,83 ± 19,08 2,36 ± 2,38 0,59 ± 0,91
SAHS, Sleep apnea-hypopnea syndrome; CPAP, Continuous positive airway
pressure; BMI, Body mass index; SBP, Systolic blood pressure; DBP, Diastolic
blood pressure; cig, Cigarettes; U, Units; AHI, Apnea-hypopnea index; OAI,
Obstructive apnea index; CAI, Central apnea index; MAI, Mixed apnea index;
HypoI, Hypopnea index; evts—/h, Events per hour; SaO2, Mean arterial blood
oxygen saturation; PLMI, Periodic leg movement index. Results expressed as
mean ± standard deviation. * P < 0,05, ** P < 0,01, *** P < 0,001 vs.
healthy controls.
Patients suffering from severe SAHS showed large values for all sleep
breathing events and increased BMI in comparison to healthy men (controls).
Patients treated by CPAP had larger BMI and DBP than controls.
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band, which is related to deep sleep. In regard to the sta-
tionary requirement for applying this method, we limited
our analysis to the three first NREM-REM cycles [42].
At the frequency of the cross-spectrum maximum be-
tween HFnu and delta signals, fNREM-REM, we calculated
coherence, gain, phase shift and the delay values between
the fluctuations in HFnu and the fluctuations in the delta
power band. The frequency of the main peak of cross-
spectrum oscillations was around a rhythm of a sleep
NREM-REM cycle and was defined below 1,1 × 10-3 Hz.
This limit corresponds to the minimal duration between
two successive REM epochs to define a new NREM-REM
cycle [46]. The coherence value could be interpreted as
the linear part of a signal that is explained by the other
signal. Values of coherence are between 0 and 1. Zero
reflects the absence of a linear link between both signals
while a coherence value of 1 suggests a very strong linear
link between HFnu and delta signals. The gain value is the
ratio between amplitude of both signals. The phase shift is
the angular phase, expressed in degrees, while the delay is
the angular phase divided by the frequency fNREM-REM and
converted to minutes. This indicates the duration between
the occurrence of modifications in both signals.
Statistics
All results are expressed as mean ± standard deviations.
For the figures, standard errors were preferred to stand-
ard deviations. P values < 0,05 are considered as statisti-
cally significant. Variables for demographic, sleep and
heart rate variability parameters as well as variables of
coherence analysis between HFnu and delta were com-
pared between untreated patients suffering from SAHS
and healthy controls and between CPAP treated patients
and controls. Heart rate variability components were
also compared between sleep stages in comparison to
NREM sleep across the first three NREM-REM cycles.
Normality, homogeneity and homoscedasticity were
tested for all groups of variables. If variables did not an-
swer to the conditions, they were transformed to log10
or non-parametric tests were used. If all conditions were
satisfied, general linear model (GLM) or T-Test for inde-
pendent variables were used. To measure a potential ef-
fect of the body mass index (BMI) on cardiac autonomic
components, bivariate correlations were applied between
BMI values and each cardiac variable.
All the statistical analyses were computed with SPSS
software (IBM SPPS Statistics, 20.0.0, USA).
Results
Demographic parameters
Eight untreated patients and the same eight patients
treated with CPAP did not differ from fourteen healthy
controls in terms of age, systolic blood pressure, andnicotine, alcohol or caffeine consumptions. BMI was
higher in both groups of patients and diastolic blood
pressure was increased only in patients receiving CPAP
compared to controls. Mean arterial blood oxygen satur-
ation (SaO2) was decreased in untreated apneic patients
compared to healthy men. Bivariate correlations showed
BMI to be unrelated to HRV components. Table 1 reports
mean values.
CPAP treatment decreased the apnea-hypopnea index
from 63,5 ± 22,9 events/hour to 5,5 ± 4,4 events/hour in
treated patients and normalized the mean SaO2. Mean
treatment duration was 4 ± 3 years. Mean compliance
duration for CPAP treatment was 6 ± 1 hours/night. The
AHI was similar between treated patients and controls.
Patients with CPAP showed an AHI between 0 and 12
events/h.
Sleep parameters
During the entire night, patients suffering from SAHS
showed decreased mean duration of REM sleep com-
pared to controls. This difference disappeared with
CPAP treatment. Other sleep parameters were similar
between untreated patients and healthy men. All sleep
parameters were similar between CPAP treated patients
and controls.
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and wake after sleep onset (WASO) durations were similar
between untreated apneic patients and controls as well as
between apneic patients treated by CPAP and controls.
Mean light sleep (stages 1 + 2) duration was increased in
untreated patients in comparison to controls while in
CPAP treated patients, light sleep duration was similar to
healthy men. Mean deep sleep (stages 3 + 4) duration was
not different among patients with SAHS, CPAP treated
patients and healthy controls (Table 2).
Heart rate variability parameters
Across the entire first three NREM-REM cycles, simi-
lar spectral cardiac components of HRV wereTable 2 Sleep parameters for the entire night and the







before CPAP with CPAP
Parameters for entire night
TIB (min) 470 ± 36 471 ± 44 466 ± 56
SPT (min) 444 ± 56 446 ± 58 444 ± 64
TST (min) 397 ± 48 401 ± 55 414 ± 61
Sleep efficiency (%) 84 ± 8 85 ± 8 87 ± 5
Sleep latency (min) 19 ± 9 23 ± 9 16 ± 10
Amount of nocturnal
awakenings
74 ± 56 38 ± 14 38 ± 16
Amount of sleep changes 231 ± 99 167 ± 57 218 ± 81
NREM duration (min) 337 ± 35 309 ± 58 322 ± 47
REM duration (min) 63 ± 28* 89 ± 11 91 ± 24
WASO duration (min) 44 ± 30 48 ± 33 30 ± 18
NREM duration (% SPT) 76 ± 8 69 ± 8 73 ± 3
Deep sleep duration (% SPT) 3 ± 4 4 ± 7 7 ± 6
REM duration (% SPT) 14 ± 6** 20 ± 5 21 ± 4
WASO duration (% SPT) 10 ± 7 10 ± 6 7 ± 4
Parameters for the first three NREM-REM cycles
Sleep cycles duration (min) 331 ± 55 316 ± 60 296 ± 35
NREM duration (min) 253 ± 43 229 ± 55 221 ± 24
Light sleep duration (min) 237 ± 65* 216 ± 58 190 ± 30
Deep sleep duration (min) 16 ± 25 13 ± 20 31 ± 24
REM duration (min) 47 ± 25 63 ± 21 63 ± 19
WASO duration (min) 31 ± 24 25 ± 17 12 ± 6
SAHS, Sleep apnea-hypopnea syndrome; CPAP, Continuous positive airway
pressure; TIB, Time in bed; SPT, Sleep period time; TST, Total sleep time; NREM,
Non rapid eye movement sleep; REM, Rapid eye movement sleep; WASO,
Wake after sleep onset; light sleep: sleep stages 1 + 2; deep sleep: sleep stages
3 + 4; min: minutes. Results were expressed as mean ± standard deviation.
* P < 0,05, ** P < 0,01 vs. healthy controls.
Patients suffering from severe SAHS showed decreased overnight REM
duration, expressed in minutes (min) or in percentage of the SPT (% SPT), and
increased light sleep duration over the first three NREM-REM cycles, in
comparison to healthy controls. All other sleep variables were similar between
untreated apneic patients and controls as well as between CPAP treated
apneic patients and controls.observed between untreated apneic patients and con-
trols as well as between patients treated by CPAP and
controls. The LF/HF ratio and mean durations of RR
intervals and HF HRV, expressed in absolute or nor-
malized units, did not differ between untreated or
CPAP treated patients and healthy controls. Neverthe-
less, in SAHS patients with and without CPAP, stand-
ard deviation of absolute HF of RRI was larger than
the mean value (Table 3).
Across sleep stages, RRI and cardiac spectral compo-
nents of HRV as well as the LF/HF ratio did not differ
between untreated patients and controls nor between
CPAP treated patients and controls. For all groups,
RRI was decreased during WASO in comparison to
NREM sleep (Figure 1). Other cardiac parameters did
not show significant differences between sleep stages
and NREM sleep (Table 3).
In patients treated with CPAP, standard deviation values
of the LF/HF ratio during REM and wake were at least as
large as the mean values of LF/HF during the same sleep
stages (Table 3).Table 3 Heart rate variability parameters
SAHS patients SAHS patients Healthy
controlsbefore CPAP with CPAP
Parameters for the first three sleep cycles
TF (ms2) 3806,73 ± 1965,05 1516,12 ± 1126,28 2740,10 ± 2006,97
VLF (ms2) 1991,91 ± 1128,84 722,10 ± 447,80 1264,10 ± 1154,44
LF (ms2) 1120,43 ± 499,85 522,31 ± 497,23 995,51 ± 629,67
HF (ms2) 589,40 ± 711,42 255,41 ± 326,06 407,04 ± 359,76
HFnu 29,63 ± 16,90 32,19 ± 16,57 26,96 ± 11,95
LF/HF 3,52 ± 2,62 3,14 ± 2,79 3,60 ± 2,30
RRI (sec) 0,95 ± 0,06 0,95 ± 0,07 1,00 ± 0,15
Parameters for the first three sleep cycles across sleep stages
NREM RRI (sec) 0,95 ± 0,06 1,01 ± 0,07 1,01 ± 0,16
REM RRI (sec) 0,96 ± 0,11 1,02 ± 0,06 0,98 ± 0,13
WASO RRI (sec) 0,92 ± 0,06 0,97 ± 0,06 0,97 ± 0,15
NREM HFnu 29,71 ± 17,52 32,81 ± 17,63 27,23 ± 12,23
REM HFnu 29,86 ± 15,86 30,93 ± 13,87 25,84 ± 13,97
WASO HFnu 30,25 ± 15,50 28,22 ± 12,28 24,86 ± 8,93
NREM LF/HF 3,84 ± 3,06 3,13 ± 2,66 3,52 ± 2,36
REM LF/HF 2,18 ± 2,38 3,09 ± 3,09 4,13 ± 3,15
WASO LF/HF 1,88 ± 1,35 3,70 ± 3,92 3,93 ± 3,18
SAHS, Sleep apnea-hypopnea syndrome; CPAP, Continuous positive airway
pressure; TF, Total power of heart rate variability (HRV); VLF, Very low
frequency power of HRV; LF, Low frequency power of HRV; HF, High frequency
power of HRV; RRI, RR-interval duration; NREM, Non rapid eye movement sleep;
REM, Rapid eye movement sleep; WASO, Wake after sleep onset; ms,
Milliseconds; nu, Normalized units. Results were expressed as mean ± standard
deviation. Comparisons were performed with healthy men (controls).
Mean RR-interval durations, spectral components of RRI (expressed in absolute
units, ms2, or normalized units) and the LF/HF ratio were similar between
untreated patients and controls as well as between CPAP treated patients and
controls throughout the night and sleep stages.
Figure 1 Mean duration of RR intervals (RRI), expressed in seconds (sec), across sleep stages in SAHS patients before CPAP, with CPAP
and healthy men (controls). SAHS: sleep apnea-hypopnea syndrome; CPAP: Continuous positive airway pressure; NREM: non rapid eye
movement sleep; REM: rapid eye movement sleep; WASO: wake after sleep onset. Mean values of the RR-interval durations were represented by
boxes while standard errors were represented by bars in regard of three sleep stages. Each box colour was specific for each group of subjects. In
each group, sleep stages (REM or WASO) were compared to NREM sleep. The symbol “$” correspond to a comparison between a specific sleep
stage (REM or WASO) with NREM in a specific group of subjects with a P value < 0,001. RRI decreased from NREM sleep to wakefulness in each
group of subjects.
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The frequency of the maximum of the cross-spectrum
between HFnu and delta, fNREM-REM, was decreased in
untreated [(1,33 ± 0,25) 10-4 Hz] and treated patients
[(1,34 ± 0,29) 10-4 Hz] compared to healthy controls vs
[(1,87 ± 0,69) 10-4 Hz, P < 0,05 for each comparison].
Moreover, untreated patients showed decreased coher-
ence and gain values in comparison to controls (Figure 2,
panel a, b). During long-term CPAP treatment, gain
values between HFnu and delta signals were similar to con-
trols while coherence values were decreased (Figure 2,
panel a, b). Phase shift between occurrence of modifica-
tions in HFnu and those in the delta power band did not
differ between untreated apneic patients and controls
(32,76 ± 85,70 vs. 33,44 ± 19,15 degrees) or between
CPAP treated patients and controls (40,40 ± 56,63 vs.
33,44 ± 19,15 degrees). Similar results were obtained for
the delay between occurrence of modifications in both
signals and are shown in Figure 2, panel c. Additionally,
standard deviations of the phase shift and delay were
larger than the corresponding mean values for untreated
and treated patients. In healthy controls, modifications
occurrence in HFnu preceded the occurrence of those in
the delta power band with a phase advance corresponding
to 9 ± 7 minutes.
Discussion
Our study revealed that long-term use of nasal CPAP
ameliorates some parameters reflecting the relationship
between heart and brain during sleep in patients sufferingfrom SAHS. Furthermore, in SAHS, the link between car-
diac vagal influence and delta sleep is altered even in the
absence of significant differences in mean spectral HRV
components between apneic patients and healthy men.
Therefore, the permanence of altered parameters such
as the tightness of the link related to coherence values,
or such as the phase shift between modification occur-
rences in HFnu and those in delta power bands, suggests
that CPAP can not completely reverse the impairment of
the relationship between heart and brain during sleep
seen in patients suffering from SAHS. However, im-
proved parameters of the relationship between cardiac
sympatho-vagal balance and delta sleep, such as the gain
between both signals, probably may contribute to the
prevention of cardiovascular events in severely apneic
patients treated with long-term CPAP.
Our patients suffering from severe SAHS showed de-
creased REM duration compared to healthy controls.
Other sleep parameters did not differ from controls.
Sleep characteristics of CPAP treated patients were simi-
lar to controls.
Our results were in accordance with the sleep archi-
tecture of patients suffering from moderate-to-severe
SAHS, treated by an oral placebo versus by nasal CPAP
for 6 to 12 months [18]. The authors of this study
reported similar results between untreated and CPAP
treated patients except a decreased deep sleep (sleep
stages 3 + 4) in placebo patients. Sleep stage 1 duration
and mean arousal index were increased in this latter
group while CPAP treatment decreased these values
Figure 2 Coherence analysis parameters between HFnu and delta power band signals. Panel a. Mean coherence value in SAHS patients
before CPAP, with CPAP and healthy men (controls). Panel b. Mean gain value, expressed as the amplitudes’ ratio between delta power band and
HFnu (Adelta/AHFnu), in SAHS patients before CPAP, with CPAP and healthy men (controls). Panel c. Mean delay, expressed in minutes (min),
between the occurrence of modifications in HFnu and those in delta power band in SAHS patients before CPAP, with CPAP and healthy men
(controls). SAHS: sleep apnea-hypopnea syndrome; CPAP: Continuous positive airway pressure. For each panel, comparisons were performed with
controls. Values were expressed as mean ± standard errors. * P < 0,05. Coherence values of the link between the relative cardiac vagal
predominance and delta power band were decreased in untreated and long-term nasal CPAP treated apneic patients compared to controls. Gain
values between these both signals decreased in untreated apneic patients in comparison to controls while during long-term nasal CPAP
treatment, gain values were similar to controls. Delay between occurrence of modifications in HFnu and those in the delta power band did not
differ between untreated apneic patients and controls or between CPAP treated patients and controls.
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http://www.biomedcentral.com/1471-2466/13/29[18]. In our sample, we observed that mean deep sleep
duration was decreased in comparison to controls but
this difference was not significant. Moreover, the lower
REM duration observed in our untreated apneic pa-
tients, which increased with CPAP treatment to become
similar to that of healthy controls, was also observed in
apneic patients treated by placebo versus CPAP treat-
ment without significant difference [18].
A previous study comparing sleep quality between
sham-CPAP and effective-CPAP treatment in patients
suffering from severe obstructive sleep apnea syndrome
(OSAS) showed an absence of difference in sleep param-
eters between sham-CPAP and effective-CPAP treatment
after seven days of treatment [51]. Nevertheless, a time
effect was reported in both groups [51]. Our comparison
between untreated patients and controls as well as be-
tween treated patients and controls confirmed the findings
that CPAP did not ameliorate sleep parameters in com-
parison to healthy men with the exception of REM dur-
ation. In our study, we were not able to differentiate the
role of CPAP treatment or the time effect of treatment.
Older publications showed increased REM duration as
well as deep sleep after the first night of nasal CPAP
treatment [17,52]. These changes were maintained after
three days of CPAP treatment [52]. Observed values
were compared with baseline and were not compared
with healthy values. These increases were explained by a
rebound effect [17,53]. Nevertheless, the authors did not
determine precisely if these values were larger than
those observed for healthy controls or if values became
normal, as in healthy controls. In our study, we con-
firmed that patients suffering from severe SAHS showed
shorter values of REM duration and that long-term
nCPAP treatment restored REM duration to that of
healthy controls.
In contrast with some data in the literature [11,12,54],
our patients suffering from SAHS did not demonstrate
significant changes of spectral cardiac components of
HRV compared to healthy men. Nevertheless, our results
were also in agreement with previous papers studying
HRV components during rest [14], across sleep stages
[16] or for normalized HRV components [12] in apneic
patients.
Our SAHS patients treated by nCPAP did not differ
significantly from healthy controls in terms of mean
HRV components. Nevertheless, in treated SAHS com-
pared to healthy subjects, there were strong trends to-
wards lower absolute HRV values and increased HFnu
(hence lowered LF/HF). Indeed, assessment within sleep
stages revealed that treated SAHS patients exhibited
consistent trends towards greater HFnu (lower LF/HF
ratio) in each sleep state. Thus, we hypothesize that
long-term nCPAP use could increase the cardiac vagal
predominance of HRV.Only a few studies evaluated the impact of long-term
CPAP treatment on cardiac sympatho-vagal activity
[19,20,25,26]. In patients suffering from OSA and heart
failure, after one month of nCPAP, HF HRV, in absolute
and normalized units, was increased during wakefulness
in the morning compared to controls. Additionally, the
LF/HF ratio was decreased [20]. During the night after
three months of nasal CPAP treatment, LF/HF, VLF, LF,
and LFnu values were decreased while HFnu was in-
creased compared to patients with moderate-to-severe
SAHS before treatment [19]. In contrast to the increased
cardiac influence, the Chrysostomakis’group found de-
creased vagal tone after two months of CPAP treatment
[25]. However, in his group of patients suffering from se-
vere obstructive SAHS, vagal activity was increased dur-
ing the night in comparison to healthy controls. CPAP
treatment produced similar cardiac vagal activity to that
of healthy controls [25]. After one, three and six months
of CPAP therapy in moderate to severe SAHS patients,
LFnu, HFnu, and the LF/HF ratio during spontaneous
and deep breathing were similar to baseline values im-
plying the absence of increased relative cardiac vagal
predominance induced by CPAP treatment [26].
Similar controversy was reported during the first days
of CPAP treatment use in SAHS patients [27,28,55].
Overnight LF and HF power values did not show differ-
ences between moderately apneic patients, severely apneic
patients, CPAP treated patients, and healthy controls after
one night of treatment [27]. In this study, patient groups
were small (5 to 8 per group) and many had cardiac
comorbidities and were treated by cardiotropic medica-
tions. Moreover, the standard deviation of LF/HF during
NREM for moderate OSA and CPAP treatment was al-
most similar to the mean values. This indicates a large
variability of cardiac sympatho-vagal balance between all
four subjects of each group. Although that mean HR dur-
ing the night as well as across sleep stages (NREM, REM,
awake) was not different before and after one night of
CPAP treatment in patients suffering from severe SAHS,
HRV was decreased with the use of CPAP [28]. After 11
days of nCPAP treatment, the LF/HF ratio was lower at
rest in the morning than the values observed after one
and three nights of treatment as well as the baseline values
before CPAP treatment [55]. Additionally, in the CPAP
treated group, HF was increased beginning on the third
day in comparison to the placebo group [55]. These results
indicated that cardiac sympatho-vagal fluctuations were
decreased in untreated apneic patients with lower vagal
tone and that CPAP treatment increased cardiac vagal
influence [55].
Thus, numerous studies reveal that vagal predomin-
ance of the cardiac sympatho-vagal balance was induced
by CPAP treatment in comparison to severely apneic
patients before treatment [19,20,55] but these results
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compared their results to healthy controls [25,27]. In
our results, cardiac sympatho-vagal activity of CPAP
treated patients did not differ from that of healthy men.
However, HFnu, which reflects cardiac vagal predomin-
ance, tended to be greater compared to healthy controls
without reaching statistical significance, a trend that
was apparent whether we assessed HRV within individ-
ual sleep states or assessed the first 3 cycles of the night
as a whole.
During the first three NREM-REM cycles, the LF/HF ra-
tio did not differ from one in CPAP treated patients. This
result indicates that none of the sympathetic and vagal
branches of cardiac sympatho-vagal activity predominated,
in contrast to the relative sympatho-vagal influence in
healthy controls. Moreover, the absence of relative sympa-
thetic or vagal predominance is found during REM sleep
and wakefulness in patients treated by CPAP. This could
imply that CPAP treatment increased cardiac vagal activity
in contrast to the relative sympathetic activity. Indeed,
CPAP treatment improved baroreflex sensitivity in SAHS
[56,57]. During SAHS, chemoreflex sensitivity is increased
and is associated with increased relative sympathetic pre-
dominance, while CPAP treatment could normalize the
sympathetic response by decreasing sensitivity and tonic
activity of the chemoreflex [9,58,59]. Moreover, readjusted
chemosensitivity during CPAP treatment could increase
baroreflex activity [58]. Then, long-term CPAP treatment
could abolish the relative sympathetic predominance and
increase the relative vagal influence of the cardiac
sympatho-vagal balance during sleep.
In accordance with previous reports [16], our patients
suffering from severe SAHS demonstrated decreased co-
herence and gain values compared to healthy men. The
phase shift or the delay between occurrence of modifica-
tions in HFnu and occurrence of those in the delta power
band did not differ from controls, but showed larger
fluctuations around the mean and did not certainly differ
from zero. In agreement with our previous paper [16],
SAHS altered the tightness of the link between cardiac
sympatho-vagal influence and delta during sleep as well
as the phase shift or the delay between occurrences of
modifications in HFnu and those in delta power band.
This may be due to a more irregular breathing. In patients
treated with long-term nCPAP, we observed decreased co-
herence and similar gain values in comparison to healthy
controls. Moreover, the variability of the phase shift or the
delay between HFnu and delta modifications was decreased
in comparison with untreated apneic patients, but phase
shift and delay were not different from zero.
Thus, long-term nCPAP increases the strength of the
interaction between the relative cardiac vagal predom-
inance of HRV and delta sleep EEG but does not en-
hance the tightness of this link. CPAP treatment couldameliorate the quality of the information between brain-
stem cardiovascular and sleep structures through a
regularisation of breathing and, as a result, an increase
in the gain values and also a decrease in the variability
of the time delay between modifications in cardiac
sympatho-vagal influence and delta power band during
sleep. Other non-linear biomathematical models that
are specifically developed to determine the exact phase
shift and the information flow of ECG-EEG signals, as
phase slope index or Granger causality, could be applied
to confirm our results [60].
Decreased frequency of the maximum of the cross-
spectrum between HFnu and delta indicated a length-
ened mean sleep cycle duration and that the time at
which both signals shared a maximum of power was
later than that of healthy controls. Then, mean delay
between modifications occurrence of HFnu and delta
signals was later in untreated and treated patients in
comparison to healthy men.
Our patients were controlled with healthy men for age,
nicotine, alcohol and caffeine consumptions. Moreover,
they did not suffer from other pathologies than severe
SAHS. They had no present or past medical condition that
would modify cardiovascular or cerebral activities. They
took no illicit drugs, psychotropic or somatic medications,
or over the counter agents that could interfere with car-
diac activity or sleep. Presumably, this “pure” sample does
not reflect the general middle-aged population. The re-
sults are also limited by the small size of our groups. On
the other hand, we can also ensure that comorbidities did
not influence our analysis of relationship between cardiac
vagal influence and delta sleep in SAHS and its adequate
CPAP treatment. Nevertheless, we were not able to match
BMI for patients and controls. The influence of BMI on
HRV is controversial [61,62]. Using bivariate correlations,
we concluded that BMI did not influence our HRV com-
ponents. Additionally, our results were in accordance with
those of the Kufoy and his group [28]. He studied HRV
components in severe apneic patients with class I obesity
before and after CPAP treatment [28]. Due to our sample
size and their characteristics, our results should be con-
firmed by large population studies and further, tested on
populations with comorbidities.
Conclusions
Our data confirm alterations of the relationship between
cardiac sympatho-vagal activity and delta power in pa-
tients suffering from severe SAHS, even in the absence
of cardiovascular events or significant changes in HRV
components. Moreover, new findings of this study reveal
that long-term nCPAP treatment could ameliorate the
interaction between heart and brain during sleep, and
thus, avoid cardiovascular pathologies, even if CPAP
treatment does not cure SAHS.
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